Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States

Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat. 2017;24(4):268-279.

Publication Type:

Journal Article

Authors:

Elbasha, E.; Greaves, W.; Roth, D.; Nwankwo, C.

Source:

J Viral Hepat, Volume 24, Issue 4, p.268-279 (2017)

Cited On:

Patients with Renal Impairment

Export Citation:

RIS Format

Top